r a t i o n a l e a n d o b j e c t i v e s . Because new diagnostic tests become available rapidly, the authors determined a need for proper assessment of tests before their implementation in clinical practice. Three factors are of pivotal importance: the selection of the proper study population, the determination of the diagnostic power including its related statistical analysts, and the relation of the new test to current diagnostic tools. Pa tients suspected of having a disease are those who would benefit from the application of a new test. Therefore, only those pa tients need be involved in the assessment study.
METHODS. Summary measures of diagnostic power other than sensitivity and specificity are advocated because these con ventional measures depend on cutoff points and are susceptible to selection bias. The relation between the new test and existing diagnostic tools must be established to determine if the new test contributes to the diagnostic process. r e s u l t s a n d c o n c l u s i o n . To avoid waste of effort and money, the authors suggest a prudent assessment approach in phases. Whereas the initial challenge consists of selection of an adequate patient population, subsequently all determinants of disease (signs, symptoms, comorbidity, and other diagnostic factors) and factors influencing the decision to use a test (pa tient burden and cost) are considered. M a n y n e w d i a g n o s t i c tests have been developed and introduced into clinical practice in recent years. Consequently, a need has developed for proper as sessment o f tests before im plem entation. While consen sus exists as to necessity o f a phased assessment of a new drug, this is not the case for diagnostic tests. Three factors are of central im portance in diagnostic test assessment:
(1) the selection of the proper study population, (2) the determ ination of diagnostic power with its related statis tical analysis, and (3) the comparison of the new test with current diagnostic tools.
For assessment of a test, usually the test results of healthy people are compared with those of patients al ready known to have a given disease: the easily accessible population. In clinical practice, however, the test is used to distinguish between the presence and absence of dis ease am ong patients having certain symptoms and m an ifesting particular signs. In this so-called " indicated" population, it is more difficult to discriminate between suspected patients with the illness and those without, be cause it is highly probable that the test outcome is asso ciated with complaints, signs, or symptoms of the study patients. It is the assessment in an indicated population in which we are ultimately interested.1 T he second point to be stressed in assessment studies is the definition of diagnostic power and the associated statistical and analytical methods. Commonly, diagnos tic power is ascribed to a qualitative diagnostic test if it yields a higher test result more frequently in the diseased group than in the nondiseased group. The results of quantitative tests often are dichotomized, usually at the 95th percentile of the test result distribution in healthy persons,2 so as to make the test a qualitative one. Dichotom ization deprives a test of its full informative content, and thus may lead to substantial loss of information. Furtherm ore, it makes assessment of results dependent on the cutoff point and susceptible to selection bias.3 Se lection bias can occur as a result of differential verifica tion for patients with positive and negative test results,4 or as a result of studying only a part of the entire disease spectrum ,5 as is done in an easily accessible population.
Finally, it also is im portant to determine the relative value o f the new test and existing diagnostic tools to de 
Diagnostic Process
Generally, patients visit a doctor because they are ex periencing certain symptoms. The doctor will, implic itly, list diseases that are typically attended by the com plaints, signs, and symptoms that the patient is encoun tering,6 A probability of disease presence, depending on the frequency with which the doctor sees these diseases, is assigned to each disease on the list. If one probability is high enough, treatm ent will be initiated. If no proba bility is high enough, a diagnostic test will be performed. Whether a probability is sufficiently high to warrant treatment or the use of a diagnostic test cann ot be deter mined in general terms. It highly depends on the benefit of the treatment, the risk or cost of the diagnostic test, and the cost of treatm ent for patients who do not actually have the disease, but may be treated because of a falsepositive test result.5,7 The assigned probabilities of dis ease presence are adjusted for each disease on the basis of a test result.
Current Assessment Practice
For assessment of a test, the test results of healthy peo ple are compared with those of patients already known to have the disease. Diagnostic power is ascribed to a qualitative diagnostic test if it yields a higher test result more frequently in the diseased group than in the non diseased group. For example, mean serum concentra tions of carcinoembryonic antigen were higher in pa tients with colorectal carcinoma than in healthy individ uals, therefore it was long believed that carcino embryonic antigen might be a suitable diagnostic test for colorectal carcinoma. The results of quantitative tests of ten are dichotomized, usually at the 95th percentile of the test result distribution in healthy persons,2 so as to make the test qualitative. Frequently, assessment is con sidered appropriate when the sensitivity and specificity of a new test are determined.
Problems W ith Current Assessment Practice
The well-known parameters, sensitivity and specific ity, o f the applied test, to be calculated from a basic table such as Table 1 , are useful for updating the probability o f disease presence according to Bayes' theorem.5,8 Table  2 shows how the probability of disease in the presence of a positive test result is calculated with Bayes' theorem in the notation of conditional probabilities. Thus, in diag nosis, a strong need exists to know the information a test result yields (eg, by giving the sensitivity and specificity). Sensitivity: proportion of diseased with positive test result = 320/ 400 = 80%.
Specificity: proportion of non-dlseased with negative test result = 540/600 = 90%.
Prevalence of disease in test-positive group = 320/380 = 84%; of ten referred to as positive predicted value.
Prevalence of disease in test-negative group = 80/620 = 13%; also known as 1 minus negative predictive value.
In assessment studies of new tests, estimates of these test " characteristics" predom inantly are presented as assess m ent results. Unfortunately, sensitivity and specificity do not always provide the relevant inform ation for this purpose, mainly because of their dependency on cutoff points and their susceptibility to selection bias.
M any diagnostic tests yield results that are not just positive or negative, but have a wider range, such as the percentage occlusion of an artery as judged from angiog raphy. To calculate sensitivity and specificity, the possi ble test results m ust be dichotomized. A cutoff point for test positivity m ust be chosen; for example, a result higher than 70% is positive and should result in patient referral for surgery. By doing so, the different diagnostic information of 50% stenosis or 90% stenosis is not taken into account. Thus, dichotom ization deprives a test of its full informative content and m ay lead to substantial loss of information. Furtherm ore, it makes assessment re sults dependent on the cutoff point and susceptible to selection bias. 4 Selection bias can occur as a result of differenti al veri fication for patients with positive and negative test re sults,4 or as a result of studying only a part of the entire disease spectrum.5 Results of a new test usually are com pared with results from patients already diagnosed with the disease: the easily accessible population. In clinical practice, however, the test is used to distinguish between the presence and absence of disease am ong patients hav ing certain sym ptom s and manifesting particular signs. In this indicated population, it is m ore difficult to dis crim inate between suspected patients with the illness and those without because test results often are associated with the complaints, symptoms, or signs of study pa tients, Consequently, sensitivity and specificity results of tests that are applied to a population that was selected differently than the population in which the test was as sessed cannot be extrapolated to the new population.9 It is the assessment result from an indicated population in which we are ultimately interested.10,11
Consider, for example, a population in which 60% has complaints. The results o f the diagnostic test used corre late perfectly with the presence or absence of complaints. Two thirds of patients with com plaints have the disease, and three quarters of patients w ithout complaints do not have the disease. The prevalence of disease is 50% (Table  3) . In this population, the sensitivity rate of the test is 80%, and the specificity rate is 60%. In a second popula tion, only 40% has complaints, therefore, the distribu tion of disease presence and absence in patients with and without complaints is the same as in the first population. Thus, two thirds of the patients with complaints have the disease and three quarters of the patients without com plaints do not have the disease (Table 4 ). In this popula tion, the sensitivity rate o f the same test is 64%, and the specificity rate is 78%. Thus, the composition o f the pa tient population is one of the determ inants of sensitivity and specificity. These param eters are not constant char acteristics of a test, but vary with the distribution o f com plaints, symptoms, and signs.
In our opinion, it also is im portant to establish the rel ative value of the new test and existing diagnostic tools to determine whether the new test contributes as a diag nostic tool. It might be possible to eliminate one or more older diagnostic tests or, indeed, the new test.
When assessing the diagnostic value o f a new test, it m ust be compared with a generally accepted reference method, or a gold standard. In m any instances, gold standards do not exist or are not ethically justifiable to carry out on all patients (eg, surgery or autopsy). In such instances, appropriate fallible reference methods may be used, such as the generally accepted diagnostic reference test, clinical follow-up for a fixed tim e period, or re sponse to therapy. 
Assessment in Phases
The m ain challenge in diagnostic test assessment is se lection of an adequate study population. Ultimately, this population consists of indicated patients. To avoid waste o f effort and money, it must be established as soon as possible whether a diagnostic test is potentially worth while. This can be achieved by a prudent assessment in several phases.12' 17 It is not necessary that all new tests undergo the entire assessment procedure. In some in stances, it is established quickly that test outcomes am ong diseased and nondiseased patients are virtually identical. In that case, the test is not yet adequate.
Test D evelopm ent
Strictly speaking, the development of a diagnostic test does not fall within the scope of test evaluation and will not be elaborated further. Nevertheless, it is important that some facts o f the new test are known before actual assessment starts. Among these are the following.
1. M inim um detection level and cross-reactivity in the case of a biochemical test: for a useful diagnos tic test, all individuals undergoing the test, regard less of whether they have the disease, should have test results that are higher than the minimum de tection level of the test. Furthermore, the biochem ical test should only react with the substance of in terest (eg, a specific serum tum or marker) and not with other substances. 2. M easurem ent errors: large random measurement errors m ake potential diagnostic tests useless be forehand. 3. Repeatability, which must be high, otherwise the test will never meet diagnostic assessment stan dards. 
Test Application in an E asily Accessible Population
To carry out an assessment in an easily accessible pop ulation can only be useful from a pragmatic and logistic point of view. If the test performs badly here, which is not uncom m on, it will certainly perform worse in the indicated population. This phase can be regarded as a "quick and dirty'' assessment method. An easily accessi ble population could be, for instance, a population of di agnosed patients and healthy individuals. We are not concerned with the occurrence of selection bias or other problems at this point. If a test does not have sufficient discriminative power in this phase of diagnostic test as sessment, the assessment procedure can be stopped. The test needs further development.
Test Application in the Indicated Population
This essential assessment phase of the " indicated11 population should take place in a population of patients who are judged eligible for the new test in a real clinical situation because of the suspicion that they have the ill ness at issue. In this phase, therefore, we are concerned with the selection of the relevant patient population. A d equate selection of patients is achieved by gathering a consecutive series of all as yet undiagnosed patients sus pected of having the disease at issue on the ground of their complaints, signs, and symptoms.18
Diagnostic Profile
At this stage of the assessment process, it is im portant to establish the contribution of the new test to the exist ing diagnostic arsenal, including other diagnostic tests, the nonclinical profile (eg, age, gender), the clinical pro file (complaints, symptoms, and signs) and comorbidity. If the new test cannot add diagnostic power to the exist ing arsenal, it should be questioned seriously whether in troduction of the test into clinical practice is desirable. Only if the test has other relevant characteristics, such as cheapness or safeness, introduction can be considered. In this phase, it also is necessary to study only patients of the proper indicated population. To obtain the diagnos tic information of the new test alone, the outcomes of all other diagnostic tests in use must be known as well, which necessitates the concurrent measurement of those tests.
M edical Technology A ssessm ent
The last challenge for the new test is a medical tech nology assessment, including selection and order of di agnostic tests, cost-effectiveness, patient's utilities or preference measurements, etc. The new test can be used as the first test after the history has been taken and phys ical examination has been carried out. However, it is also possible that the new test is so expensive that to apply it to all patients is not justified, such as in cases where the natural course of the disease is not life-threatening. In this phase, questions of therapeutic efficacy (did treat m ent or patient m anagem ent change?), patient outcom e efficacy (did life expectancy improve?) and, if possible, societal efficacy (are costs acceptable for society?) should be answered. 19 Because there are so m any questions involved in the final phase of test assessment, the best way to deal with them probably is to carry out a clinical trial in the indi cated population, with random allocation of the new test. Test results will have therapeutic consequences and the only proper way to study such an intended effect is a random ized controlled trial.
Necessary Knowledge
Before test assessment can be carried out in any study population, certain inform ation has to be made explicit. First, the population in which the test is assessed should be defined carefully. Also, the ultim ate realization of the study population has to be described, while indicating whether the investigators succeeded in gathering all con secutive patients or not. This gives an indication of the potential selection bias contracted by the actual study population. Even an indicated population will yield bi ased assessment results when selective uptake or loss o f participants has taken place* Secondly, the diagnostic test m ust be described clearly and test results presented accordingly. This includes specifying the type of results it yields. Test results may be measured qualitatively or quantitatively. M any tests are quantitative but have been converted to qualitative tests. An example of such a test is the hemoglucotest, which measures glucose concentration in blood. The test is de signed so that at a certain blood glucose concentration the color of the test strip changes to blue.
If tests are inherently qualitative, it is possible to assign a judgm ent probability of the presence of disease to the test result to create a quantitative test result. should be trained by experienced observers and every once in a while consensus meetings might be arranged. However, interobserver variation will never be elimi nated entirely. If an apparatus is simple to read, interob server variation may not be a problem, but systematic measurement errors of the apparatus should be known for the machine to be calibrated as often as necessary. Standardization is im portant to eliminate systematic differences, but for tests involving a reader's subjective interpretation, interobserver variation cannot be elimi nated. Here, consensus and dual reading are tools for standardization.
Finally, the m anner o f verification of disease status should be stated for all patients in the investigation. Sometimes all patients can be subjected to the gold stan dard, but often, for ethical reasons, clinical follow-up for a restricted period of tim e must be used as the criterion, at least for part of the study population, and in particular for patients with negative test results. Occasionally, veri fication relies on the prescription of and subsequent re action to a medication, for instance a certain pharm a ceutical Calculation of test param eters such as sensitivity and specificity should not be restricted to those patients who were subjected to the real gold standard. In that case, the param eter estimates will be biased; this type of bias is called verification bias. 20 All relevant patient characteristics, test results, and the ultimate diagnosis should be registered individually for every patient, including missing data. W ith all this infor mation available, insight is gained into the potential bias of assessment measures, and the extent and direction of possible bias.
Statistical Analyses
For qualitative tests-measuring the test result on a presence/absence scale-com m only used measures of test performance are sensitivity and specificity, calcu lated from a fourfold ordinal categories or on a continuous scale, it is recom m ended to present all the information they provide. This can be achieved by presenting receiver operating charac teristic (ROC) curves22 and cumulative probability dis tributions.23 An RO C curve displays sensitivity versus 1 minus specificity at as m any cutoff points as possible.22,24 Re ceiver operating characteristic curves are thus indepen dent of cutoff points and yield the area under the curve as a sum m ary m easure of diagnostic performance.25,26 The construction of R O C curves is as follows. Consider the Duplex test for assessment of carotid stenosis. This test was assessed in 77 carotid arteries end carotid angiogra phy was perform ed in all of them as the gold standard. The new test m ust be able to determine whether a patient should have a carotid endarterectomy (stenosis 71 to 99%) or not (Table 5) . At each possible cutoff point the table is condensed to a 2 X 2 table and sensitivity and specificity are calculated. For example, when the Duplex criterion of >30% stenosis is used as cutoff point for test positivity, the table simplifies to Table 6 . The sensitivity then is 100% and the specificity is 37%. Next, sensitivity and 100% m inus specificity are plotted against each other in an RO C curve (Figure 1) .
Furtherm ore, different tests assessed in one popula tion can be com pared easily, and the ROC curve is rela tively stable to verification bias.3'4 Cumulative frequency distributions provide clinicians with the sensitivity and specificity of a test at any cutoff point requested.
There is a tendency to present the prevalence of illness by groups of test results,1 because this is the proportion we are naturally interested in: given a certain test result, what is the probability that disease is present? This makes sense only when the actual study population has been gathered in ignorance, and therefore indepen dently, of the true disease status.
Prevalence of disease can be calculated for patients with a positive test result and for patients with a negative test result, as well as for the various categories of test re sults for a quantitative test. In the case of a perfectly dis crim inating test, prevalence in the lower categories of the test result would be 0, whereas the prevalence of disease S e n s itiv ity (% ) 1 0 0 % m in u s S p e c ific ity in the higher would be L If the prevalence of disease con ditional on clinical and nonclinical profile, comorbidity, and other diagnostic test results is required, logistic re gression analysis is an attractive way of estimating this so-called prevalence function.10 According to the pres ence or absence of a feature or the result of a diagnostic test for an individual patient, data is substituted in the prevalence function, and the probability of having the disease can be calculated. 27 As in all analyses, missing values on test outcome or disease status have to be dealt with properly, for instance as separate categories, rather than removed from the analyses and wholly disregarded.28
Conclusion
Guidelines have been presented with recommenda tions for the design and statistical analysis of assessment studies. With respect to the patient population, it was ex plained that patients with a clinical indication for the test form the only adequate population. Patients have an in dication for a test because they are suspected of having the disease that the test is supposed to diagnose. W ith respect to the statistical analysis, a plea for the use of ROC curves and logistic regression analysis was made. Receiver operating characteristic curves use the full in formation content of a diagnostic test, in case the test is measured on an ordinal or continuous scale. With logis tic regression analysis, the contribution of the new test to the existing diagnostic arsenal can be estimated.
Good guidelines for diagnostic test assessment could prevent the introduction of disappointing diagnostic tests before they are fully im plem ented in clinical prac tice.29 Although a phased assessment is not foolproof, it is highly likely that the chances of detecting a useless test are increased by introducing such an assessment proce dure. This is illustrated aptly by the example of phased medical drug evaluation.
